Patents by Inventor Mireille Thomas

Mireille Thomas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of identifying a MHC class I restricted T cell response
    Patent number: 7892828
    Abstract: Described are peptides and polypeptides derived from the MUC-1 polypeptide which are able to activate Cytotoxic T Lymphocyte (CTL) response, analogues of such peptides and polypeptides nucleotide sequences encoding such peptides and polypeptides and therapeutic uses thereof. Moreover, indications for selecting appropriate minimal antigenic MUC-1 polypeptides with reference to the HLA-type of the patient to be treated or tested are described.
    Type: Grant
    Filed: October 13, 2009
    Date of Patent: February 22, 2011
    Assignees: Transgene S.A., Imperial Cancer Research Technology. Ldt.
    Inventors: Joyce Taylor-Papadimitriou, Lukas Carl Heukamp, Rienk Offringa, Cornelis Johanna Maria Melief, Bruce Acres, Mireille Thomas
  • METHOD OF IDENTIFYING A MHC CLASS I RESTRICTED T CELL RESPONSE
    Publication number: 20100255501
    Abstract: Described are peptides and polypeptides derived from the MUC-1 polypeptide which are able to activate Cytotoxic T Lymphocyte (CTL) response, analogues of such peptides and polypeptides nucleotide sequences encoding such peptides and polypeptides and therapeutic uses thereof. Moreover, indications for selecting appropriate minimal antigenic MUC-1 polypeptides with reference to the HLA-type of the patient to be treated or tested are described.
    Type: Application
    Filed: October 13, 2009
    Publication date: October 7, 2010
    Applicants: Transgene S.A., Imperial Cancer Research Technology, Ltd.
    Inventors: Joyce Taylor-Papadimitriou, Lukas Carl Heukamp, Rienk Offringa, Cornelis Johanna Maria Melief, Bruce Acres, Mireille Thomas
  • METHOD OF IDENTIFYING A MHC CLASS I RESTRICTED T CELL RESPONSE
    Publication number: 20080227082
    Abstract: Described are peptides and polypeptides derived from the MUC-1 polypeptide which are able to activate Cytotoxic T Lymphocyte (CTL) response, analogues of such peptides and polypeptides nucleotide sequences encoding such peptides and polypeptides and therapeutic uses thereof. Moreover, indications for selecting appropriate minimal antigenic MUC-1 polypeptides with reference to the HLA-type of the patient to be treated or tested are described.
    Type: Application
    Filed: March 4, 2008
    Publication date: September 18, 2008
    Applicants: Transgene S.A., Imperial Cancer Research Technology, Ltd.
    Inventors: Joyce TAYLOR-PAPADIMITRIOU, Lukas Carl Heukamp, Rienk Offringa, Cornelis Johanna Maria Melief, Bruce Acres, Mireille Thomas
  • MUC-1 derived peptides
    Publication number: 20050142640
    Abstract: Described are peptides and polypeptides derived from the MUC-1 polypeptide which are able to activate Cytotoxic T Lymphocyte (CTL) response, analogues of such peptides and polypeptides nucleotide sequences encoding such peptides and polypeptides and therapeutic uses thereof. Moreover, indications for selecting appropriate minimal antigenic MUC-1 polypeptides with reference to the HLA-type of the patient to be treated or tested are described.
    Type: Application
    Filed: February 11, 2005
    Publication date: June 30, 2005
    Applicants: Transgene S.A., Imperial Cancer Research Technology, Ltd.
    Inventors: Joyce Taylor-Papadimitriou, Lukas Heukamp, Rienk Offringa, Cornelis Melief, Bruce Acres, Mireille Thomas